Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption

Nikolai A. Podoltsev; Xiaoyi Wang; Rong Wang; Jonathan N. Hofmann; Linda M. Liao; Amer M. Zeidan; Ruben Mesa; Xiaomei Ma

doi:10.1002/ijc.32974

Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption

Nikolai A. Podoltsev, Xiaoyi Wang, Rong Wang, Jonathan N. Hofmann, Linda M. Liao, Amer M. Zeidan, Ruben Mesa, Xiaomei Ma

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	3523
Number of pages	1
Journal	International Journal of Cancer
Volume	146
Issue number	12
DOIs	https://doi.org/10.1002/ijc.32974
State	Published - Jun 15 2020
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/ijc.32974

Cite this

Reply to comments on : Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. / Podoltsev, Nikolai A.; Wang, Xiaoyi; Wang, Rong; Hofmann, Jonathan N.; Liao, Linda M.; Zeidan, Amer M.; Mesa, Ruben; Ma, Xiaomei.

In: International Journal of Cancer, Vol. 146, No. 12, 15.06.2020, p. 3523.

Research output: Contribution to journal › Letter › peer-review

@article{a8df7b91f1884d0999f8809544406cb7,

title = "Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption",

author = "Podoltsev, {Nikolai A.} and Xiaoyi Wang and Rong Wang and Hofmann, {Jonathan N.} and Liao, {Linda M.} and Zeidan, {Amer M.} and Ruben Mesa and Xiaomei Ma",

note = "Funding Information: N.A.P. received research funding (institutional) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI Biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals and Kartos Therapeutics. N.A.P. had a consultancy with and received honoraria from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol‐Myers Squib and CTI biopharma. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer‐Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer‐Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis and Epizyme. A.M.Z received travel support for meetings from Pfizer, Novartis, Celgene and Trovagene. RM had a consultancy with Novartis, Sierra Oncology, La Jolla and Pharma. R.M. received research funding from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior and CTI. ",

year = "2020",

month = jun,

day = "15",

doi = "10.1002/ijc.32974",

language = "English (US)",

volume = "146",

pages = "3523",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "12",

}

TY - JOUR

T1 - Reply to comments on

T2 - Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption

AU - Podoltsev, Nikolai A.

AU - Wang, Xiaoyi

AU - Wang, Rong

AU - Hofmann, Jonathan N.

AU - Liao, Linda M.

AU - Zeidan, Amer M.

AU - Mesa, Ruben

AU - Ma, Xiaomei

N1 - Funding Information: N.A.P. received research funding (institutional) from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Jazz Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTI Biopharma, Celgene, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals and Kartos Therapeutics. N.A.P. had a consultancy with and received honoraria from Pfizer, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, Celgene, Bristol‐Myers Squib and CTI biopharma. A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer‐Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer‐Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis and Epizyme. A.M.Z received travel support for meetings from Pfizer, Novartis, Celgene and Trovagene. RM had a consultancy with Novartis, Sierra Oncology, La Jolla and Pharma. R.M. received research funding from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior and CTI.

PY - 2020/6/15

Y1 - 2020/6/15

UR - http://www.scopus.com/inward/record.url?scp=85082512786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082512786&partnerID=8YFLogxK

U2 - 10.1002/ijc.32974

DO - 10.1002/ijc.32974

M3 - Letter

C2 - 32167580

AN - SCOPUS:85082512786

VL - 146

SP - 3523

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -